glp 1 ra with cvd benefit Glucagon-like peptide receptor agonists: cardiovascular benefits and mechanisms of action GLP-1 receptor agonists and cardiovascular...

Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760

The oily skin is characterized by excessive sebum production by the sebaceous glands , i.e., hyperseborrhea

Secondary Loss of Response Secondary loss of response means a peptide worked initially, then stopped

Cornell study: GLP-1 drugs will significantly reshape consumer food demand The study found that households with at least one GLP-1 user typically reduce grocery spending by 5.5% within six months of adoption, with higher-income households reducing spending by 8.6%